MA54960A - Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine - Google Patents

Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine

Info

Publication number
MA54960A
MA54960A MA054960A MA54960A MA54960A MA 54960 A MA54960 A MA 54960A MA 054960 A MA054960 A MA 054960A MA 54960 A MA54960 A MA 54960A MA 54960 A MA54960 A MA 54960A
Authority
MA
Morocco
Prior art keywords
pyrrolo
pyrimidine
amine derivative
amine
derivative
Prior art date
Application number
MA054960A
Other languages
English (en)
Inventor
Hirokazu Fuchida
Shoki Hara
Hidefumi Kasuga
Yu KOBAYAKAWA
Takashi Mizutani
Yoshio Ogino
Fuyuki Yamamoto
Original Assignee
Taiho Pharmaceutical Co Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Taiho Pharmaceutical Co Ltd filed Critical Taiho Pharmaceutical Co Ltd
Publication of MA54960A publication Critical patent/MA54960A/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/66—Phosphorus compounds
    • A61K31/675—Phosphorus compounds having nitrogen as a ring hetero atom, e.g. pyridoxal phosphate
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/53—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with three nitrogens as the only ring hetero atoms, e.g. chlorazanil, melamine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5375—1,4-Oxazines, e.g. morpholine
    • A61K31/5377—1,4-Oxazines, e.g. morpholine not condensed and containing further heterocyclic rings, e.g. timolol
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
    • A61K31/5395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines having two or more nitrogen atoms in the same ring, e.g. oxadiazines
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D498/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms
    • C07D498/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and oxygen atoms as the only ring hetero atoms in which the condensed system contains two hetero rings
    • C07D498/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Epidemiology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
MA054960A 2019-02-15 2020-02-14 Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine MA54960A (fr)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
JP2019025844 2019-02-15

Publications (1)

Publication Number Publication Date
MA54960A true MA54960A (fr) 2021-12-22

Family

ID=72044229

Family Applications (1)

Application Number Title Priority Date Filing Date
MA054960A MA54960A (fr) 2019-02-15 2020-02-14 Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine

Country Status (14)

Country Link
US (1) US11786534B2 (fr)
EP (1) EP3925669A4 (fr)
JP (1) JP6960064B2 (fr)
KR (1) KR102645237B1 (fr)
CN (1) CN113453764B (fr)
AU (1) AU2020221744B2 (fr)
BR (1) BR112021015813A2 (fr)
CA (1) CA3130049C (fr)
MA (1) MA54960A (fr)
MX (1) MX2021009752A (fr)
PH (1) PH12021551957A1 (fr)
SG (1) SG11202108648TA (fr)
TW (1) TWI828861B (fr)
WO (1) WO2020166680A1 (fr)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2023204303A1 (fr) 2022-04-22 2023-10-26 大鵬薬品工業株式会社 Cristal de dérivé de 7h-pyrrolo[2,3-d]pyrimidine-4-amine
WO2023204304A1 (fr) 2022-04-22 2023-10-26 大鵬薬品工業株式会社 Procédé de production d'un dérivé de 7h-pyrrolo[2,3-d]pyrimidine-4-amine
WO2025072720A1 (fr) * 2023-09-29 2025-04-03 Taiho Pharmaceutical Co., Ltd. Cristaux de dérivés de 7h-pyrrolo [2,3-d] pyrimidin-4-amine
WO2025127108A1 (fr) * 2023-12-13 2025-06-19 大鵬薬品工業株式会社 Agent de traitement de tumeur à migration cérébrale contenant, en tant que principe actif, du n-(4-(4-amino-6-éthynyl-5-(quinolin-3-yl)-7h-pyrrolo[2,3-d]pyrimidin-7-yl)bicyclo[2.2.1]heptan-1-yl)-5-méthylpyrazine-2-carboxamide ou un sel de celui-ci

Family Cites Families (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US8575164B2 (en) 2005-12-19 2013-11-05 OSI Pharmaceuticals, LLC Combination cancer therapy
JP2009520028A (ja) 2005-12-19 2009-05-21 オーエスアイ・ファーマスーティカルズ・インコーポレーテッド Ｉｇｆｒ抑制剤および抗癌剤の併用
TW201336847A (zh) * 2012-02-07 2013-09-16 Taiho Pharmaceutical Co Ltd 喹啉基吡咯并嘧啶化合物或其鹽
EA201590855A1 (ru) 2012-11-15 2015-11-30 Фармасайкликс, Инк. Соединения пирролопиримидина как ингибиторы киназ
EP3145512B1 (fr) * 2014-05-19 2019-07-17 Jiangsu Hengrui Medicine Co., Ltd. Composés éthynyle hétérobicycliques substitués en tant qu'inhibiteurs de la tyrosine kinase
WO2018079310A1 (fr) 2016-10-31 2018-05-03 大鵬薬品工業株式会社 Inhibiteur sélectif de l'egfr mutant par insertion de l'exon 20

Also Published As

Publication number Publication date
US11786534B2 (en) 2023-10-17
WO2020166680A1 (fr) 2020-08-20
CN113453764A (zh) 2021-09-28
PH12021551957A1 (en) 2022-05-23
KR102645237B1 (ko) 2024-03-07
SG11202108648TA (en) 2021-09-29
TW202045509A (zh) 2020-12-16
JPWO2020166680A1 (ja) 2021-11-04
MX2021009752A (es) 2021-09-08
JP6960064B2 (ja) 2021-11-05
CA3130049C (fr) 2024-04-16
CN113453764B (zh) 2024-04-16
AU2020221744B2 (en) 2022-06-23
AU2020221744A1 (en) 2021-09-23
EP3925669A1 (fr) 2021-12-22
TWI828861B (zh) 2024-01-11
BR112021015813A2 (pt) 2021-10-13
US20220160719A1 (en) 2022-05-26
KR20210116598A (ko) 2021-09-27
CA3130049A1 (fr) 2020-08-20
EP3925669A4 (fr) 2022-10-26

Similar Documents

Publication Publication Date Title
MA47500A (fr) Dérivés de pyrrolo [1,2-b]pyridazine
IL276802A (en) Transduced 2,1-dihydro-3h-pyrazolo[4,3-d]pyrimidin-3-ones
EP3980010A4 (fr) Composés de pyrazolo[1,5-a]pyrimidine 2,3,5-trisubstitués
IL260923B (en) History of pyrazolo[5,1-a]pyrazin-4-yl as jak inhibitors
HUE051424T2 (hu) RET kináz inhibitor szubsztituált pirazolo[1,5-a]piridin vegyületek
DK3523302T3 (da) Substituerede pyrazolo[1,5-A]pyridin-forbindelser som RET-kinase-inhibitorer
IL289456A (en) Eif4e-inhibiting 4-oxo-3,4-dihydropyrido[3,4-d]pyrimidine compounds
ZA202105339B (en) Imidazo[2,1-f][1,2,4]triazin-4-amine derivatives as tlr7 agonist
IL290445A (en) [1,2,4]triazolo[1,5-c]quinazolin-5-amines
MA54960A (fr) Dérivé de 7h-pyrrolo [2,3-d] pyrimidine-4-amine
EP3744723A4 (fr) Composé macrocyclique de pyrazolo [1,5-a]pyrimidine substitué
LT3820872T (lt) Pirolo[1,2-b]piridazino dariniai
IL262673A (en) A pyrazolo[5,1-a]pyrimidine compound
DK3679042T3 (da) Imidazo[1,5-A]pyrazin-derivater som PI3Kdelta-inhibitorer
EP3196199A4 (fr) N-(pyrrolidin-3-yl)-7h-pyrrolo[2,3-d]pyrimidine-4-amine substituée utilisée en tant qu'inhibiteur de la janus kinase
DK3459953T3 (da) Hidtil ukendt 5h-pyrrolo[2,3-d]pyrimidin-6(7h)-on-derivat
EP3903788A4 (fr) Composé macrocyclique de pyrazolo[1,5-a] pyrimidine
HUE052997T2 (hu) JAK kináz inhibitor pirazol[1,5-a]pirimidin származékok